Immune responses against virus and tumor in cervical carcinogenesis: Treatment strategies for avoiding the HPV-induced immune escape

Gynecologic Oncology

Volumn 131, Issue 2, 2013, Pages 480-488

  Conesa Zamora, Pablo ^a,b  

^a Santa Lucia University Hospital HGUSL   (Spain)

^b CATHOLIC UNIVERSITY OF MURCIA   (Spain)

Author keywords

Cervical cancer; Dendritic cells; Human papilloma virus; Immune system; Squamous intraepithelial lesions; Vaccines

Indexed keywords

CYCLOPHOSPHAMIDE; DNA VACCINE; IMIQUIMOD; NUCLEOTIDE; PEPTIDE VACCINE; POLYMER; TUMOR ANTIGEN; VIRUS VECTOR;

CANCER MORTALITY; CARCINOGENESIS; CLINICAL TRIAL; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DOWN REGULATION; GENOTYPE; HIGH RISK PATIENT; HUMAN; IMMUNE EVASION; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNIZATION; IMMUNOLOGICAL TOLERANCE; IMMUNOTHERAPY; MICROORGANISM; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; SEXUALLY TRANSMITTED DISEASE; UTERINE CERVIX CANCER; VACCINATION; VIRAL CLEARANCE; VIRUS INFECTION; WART VIRUS;

CERVICAL CANCER; DENDRITIC CELLS; HUMAN PAPILLOMA VIRUS; IMMUNE SYSTEM; SQUAMOUS INTRAEPITHELIAL LESIONS; VACCINES;

CANCER VACCINES; CARCINOGENESIS; FEMALE; HUMAN PAPILLOMAVIRUS 6; HUMANS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; TUMOR ESCAPE; UTERINE CERVICAL NEOPLASMS;

EID: 84886100969     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2013.08.025     Document Type: Review

References (70)

1. F.X. Bosch, A.N. Burchell, and M. Schiffman Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia Vaccine 26 2008 K1 K16
2. R.W. Tindle Immune evasion in human papillomavirus-associated cervical cancer Nat Rev Cancer 2 2002 59 65
3. P. Conesa-Zamora Role of cell cycle biomarkers in human papillomavirus related uterine lesions Curr Pharm Des 19 2013 1412 1424
4. J. Doorbar Molecular biology of human papillomavirus infection and cervical cancer Clin Sci 110 2006 525 541
5. J. Peto, C. Gilham, and J. Deacon Cervical HPV infection and neoplasia in a large population-based prospective study: the Manchester cohort Br J Cancer 91 2004 942 953
6. S.Y. Zhang, E. Jouanguy, and V. Sancho-Shimizu Human Toll-like receptor-dependent induction of interferons in protective immunity to viruses Immunol Rev 220 2007 225 236
7. R. Medzhitov, and C. Janeway Jr. Innate immunity N Engl J Med 343 2000 338 344
8. M.A. Degli-Esposti, and M.J. Smyth Close encounters of different kinds: dendritic cells and NK cells take centre stage Nat Rev Immunol 5 2005 112 124
9. M. Cella, D. Scheidegger, K. Palmer-Lehmann, P. Lane, A. Lanzavecchia, and G. Alber Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation J Exp Med 184 1996 747 752
10. B.T. Fife, and J.A. Bluestone Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways Immunol Rev 224 2008 166 182
11. F. Broere, S.G. Apasov, M.V. Sitkovsky, and W.T. van Eden cell subsets and T cell-mediated immunity F.P. Nijkamp, M.J. Parnham, Principles of Immunopharmacology 3rd Revised and Extended Ed. 2011 Springer Basel 15 27
12. C. Natale, T. Giannini, A. Lucchese, and D. Kanduc Computer-assisted analysis of molecular mimicry between human papillomavirus 16 E7 oncoprotein and human protein sequences Immunol Cell Biol 78 2000 580 585
13. M. Nees, J.M. Geoghegan, T. Hyman, S. Frank, L. Miller, and C.D. Woodworth Papillomavirus type 16 oncogenes downregulate expression of interferon-responsive genes and upregulate proliferation-associated and NF-kappaB-responsive genes in cervical keratinocytes J Virol 75 2001 4283 4296
14. P. Barnard, E. Payne, and N.A. McMillan The human papillomavirus E7 protein is able to inhibit the antiviral and anti-growth functions of interferon-alpha Virology 277 2000 411 419
15. U.A. Hasan, E. Bates, and F. Takeshita TLR9 expression and function is abolished by the cervical cancer-associated human papillomavirus type 16 J Immunol 178 2007 3186 3197
16. G.H. Ashrafi, M.R. Haghshenas, B. Marchetti, P.M. O'Brien, and M.S. Campo E5 protein of human papillomavirus type 16 selectively downregulates surface HLA class I Int J Cancer 113 2005 276 283
17. C. Heller, T. Weisser, and A. Mueller-Schickert Identification of key amino acid residues that determine the ability of high risk HPV16-E7 to dysregulate major histocompatibility complex class I expression J Biol Chem 286 2011 10983 10997
18. S. Monnier-Benoit, F. Mauny, and D. Riethmuller Immunohistochemical analysis of CD4 + and CD8 + T-cell subsets in high risk human papillomavirus-associated pre-malignant and malignant lesions of the uterine cervix Gynecol Oncol 102 2006 22 31
19. Y.L. Woo, M. van den Hende, and J.C. Sterling A prospective study on the natural course of low-grade squamous intraepithelial lesions and the presence of HPV16 E2-, E6- and E7-specific T-cell responses Int J Cancer 126 2010 133 141
20. S.J. Piersma, M.J. Welters, and S.H. van der Burg Tumor-specific regulatory T cells in cancer patients Hum Immunol 69 2008 241 249
21. N. Casares, L. Arribillaga, and P. Sarobe CD4 +/CD25 + regulatory cells inhibit activation of tumor-primed CD4 + T cells with IFN-gamma-dependent antiangiogenic activity, as well as long-lasting tumor immunity elicited by peptide vaccination J Immunol 171 2003 5931 5939
22. F. Nadais Rda, A.B. Campaner, S. Piato, M.A. Longo Galvão, R.E. dos Santos, and T. Aoki Langerhans' cells and smoking in intraepithelial neoplasia of the cervix Gynecol Oncol 102 2006 356 360
23. M.M. Madeleine, B. Brumback, and K.L. Cushing-Haugen Human leukocyte antigen class II and cervical cancer risk: a population-based study J Infect Dis 186 2002 1565 1574
24. M.H. Einstein, S. Leanza, and L.G. Chiu Genetic variants in TAP are associated with high-grade cervical neoplasia Clin Cancer Res 15 2009 1019 1023
25. S. Shrestha, C. Wang, B. Aissani, C.M. Wilson, J. Tang, and R.A. Kaslow Interleukin-10 gene (IL10) polymorphisms and human papillomavirus clearance among immunosuppressed adolescents Cancer Epidemiol Biomarkers Prev 16 2007 1626 1632
26. P. Conesa-Zamora, V. Santaclara, E. Gadea-Niñoles, S. Ortiz-Reina, and M. Perez-Guillermo Association of polymorphism in FcGR3A gene and progression of low-grade precursor lesions of cervical carcinoma Hum Immunol 71 2010 314 317
27. S. Pandey, R.D. Mittal, and M. Srivastava Impact of Toll-like receptors [TLR] 2 (- 196 to - 174 del) and TLR 4 (Asp299Gly, Thr399Ile) in cervical cancer susceptibility in North Indian women Gynecol Oncol 114 2009 501 505
28. T.H. Su, T.Y. Chang, and Y.J. Lee CTLA-4 gene and susceptibility to human papillomavirus-16-associated cervical squamous cell carcinoma in Taiwanese women Carcinogenesis 28 2007 1237 1240
29. I.H. Frazer Measuring serum antibody to human papillomavirus following infection or vaccination Gynecol Oncol 118 2010 S8 S11
30. R.P. Viscidi, M. Schiffman, and A. Hildesheim Seroreactivity to human papillomavirus (HPV) types 16, 18, or 31 and risk of subsequent HPV infection: results from a population-based study in Costa Rica Cancer Epidemiol Biomarkers Prev 13 2004 324 327
31. A. Bergot, and A. Kassianos New approaches to immunotherapy for HPV associated cancer Cancers 2011 3461 3495
32. J. Chen, G. Ni, and X.S. Liu Papillomavirus virus like particle-based therapeutic vaccine against human papillomavirus infection related diseases: immunological problems and future directions Cell Immunol 269 2011 5 9
33. E.D. Gersch, L. Gissmann, and R.L. Garcea New approaches to prophylactic human papillomavirus vaccines for cervical cancer prevention Antivir Ther 17 2012 425 434
34. C.J. Melief, and S.H. van der Burg Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines Nat Rev Cancer 8 2008 351 360
35. T.W. Dubensky Jr., and S.G. Reed Adjuvants for cancer vaccines Semin Immunol 22 2010 155 161
36. S. Chen, R. Ou, and J. Tang Enhanced anti-tumor effects of HPV16E7(49-57)-based vaccine by combined immunization with poly(I:C) and oxygen-regulated protein 150 Cancer Epidemiol 37 2013 172 178
37. J.H. Su, A. Wu, and E. Scotney Immunotherapy for cervical cancer: research status and clinical potential BioDrugs 24 2010 109 129
38. Y. Liu, S. Tuve, and J. Persson Adenovirus-mediated intratumoral expression of immunostimulatory proteins in combination with systemic Treg inactivation induces tumor-destructive immune responses in mouse models Cancer Gene Ther 18 2011 407 418
39. C.J. Hsieh, T.W. Kim, and C.F. Hung Enhancement of vaccinia vaccine potency by linkage of tumor antigen gene to gene encoding calreticulin Vaccine 22 2004 3993 4001
40. C. Sharma, B. Dey, M. Wahiduzzaman, and N. Singh Human papillomavirus 16 L1-E7 chimeric virus like particles show prophylactic and therapeutic efficacy in murine model of cervical cancer Vaccine 30 2012 5417 5424
41. I.I. Daud, M.E. Scott, Y. Ma, S. Shiboski, S. Farhat, and A.B. Moscicki Association between Toll-like receptor expression and human papillomavirus type 16 persistence Int J Cancer 128 2011 879 886
42. J. Yan, D.K. Reichenbach, and N. Corbitt Induction of antitumor immunity in vivo following delivery of a novel HPV-16 DNA vaccine encoding an E6/E7 fusion antigen Vaccine 27 2009 431 440
43. C. Trimble, C.T. Lin, and C.F. Hung Comparison of the CD8 + T cell responses and antitumor effects generated by DNA vaccine administered through gene gun, biojector, and syringe Vaccine 21 2003 4036 4042
44. Y.K. Cheung, S.C. Cheng, F.W. Sin, and Y. Xie Plasmid encoding papillomavirus Type 16 (HPV16) DNA constructed with codon optimization improved the immunogenicity against HPV infection Vaccine 23 2004 629 638
45. T.C. Wu, F.G. Guarnieri, and K.F. Staveley-O'Carroll Engineering an intracellular pathway for major histocompatibility complex class II presentation of antigens Proc Natl Acad Sci U S A 92 1995 11671 11675
46. J.H. Kim, T.H. Kang, and K.H. Noh Enhancement of dendritic cell-based vaccine potency by anti-apoptotic siRNAs targeting key pro-apoptotic proteins in cytotoxic CD8(+) T cell-mediated cell death Immunol Lett 122 2009 58 67
47. T.H. Schreiber, L. Raez, J.D. Rosenblatt, and E.R. Podack Tumor immunogenicity and responsiveness to cancer vaccine therapy: the state of the art Semin Immunol 22 2010 105 112
48. R. Mikysková, M. Indrová, and J. Símová Treatment of minimal residual disease after surgery or chemotherapy in mice carrying HPV16-associated tumours: cytokine and gene therapy with IL-2 and GM-CSF Int J Oncol 24 2004 161 167
49. S. Hallez, O. Detremmerie, and C. Giannouli Interleukin-12-secreting human papillomavirus type 16-transformed cells provide a potent cancer vaccine that generates E7-directed immunity Int J Cancer 81 1999 428 437
50. E.Y. Chang, C.H. Chen, and H. Ji Antigen-specific cancer immunotherapy using a GM-CSF secreting allogeneic tumor cell-based vaccine Int J Cancer 86 2000 725 730
51. S. Hamdy, A. Haddadi, R.W. Hung, and A. Lavasanifar Targeting dendritic cells with nano-particulate PLGA cancer vaccine formulations Adv Drug Deliv Rev 63 2011 943 955
52. M. van Seters, M. van Beurden, and F.J. ten Kate Treatment of vulvar intraepithelial neoplasia with topical imiquimod N Engl J Med 358 2008 1465 1473
53. Z.J. D'Costa, C.M. Leong, J. Shields, C. Matthews, and M.H. Hibma Screening of drugs to counteract human papillomavirus 16 E6 repression of E-cadherin expression Invest New Drugs 30 2012 2236 2251
54. E. Guzmán-Olea, V.H. Bermúdez-Morales, O. Peralta-Zaragoza, K. Torres-Poveda, and V. Madrid-Marina Molecular mechanism and potential targets for blocking HPV-induced lesion development J Oncol 2012 2012 278312
55. W. Gu, L. Putral, and N. McMillan siRNA and shRNA as anticancer agents in a cervical cancer model Methods Mol Biol 442 2008 159 172
56. S. Peng, S. Lyford-Pike, and B. Akpeng Low-dose cyclophosphamide administered as daily or single dose enhances the antitumor effects of a therapeutic HPV vaccine Cancer Immunol Immunother 62 2013 171 182
57. V.M. Jovasevic, L. Gorelik, J.A. Bluestone, and M.B. Mokyr Importance of IL-10 for CTLA-4-mediated inhibition of tumor-eradicating immunity J Immunol 172 2004 1449 1454
58. + T cell sequestration, dysfunction and deletion Nat Med 19 2013 465 472
59. J.L. Brun, V. Dalstein, and J. Leveque Regression of high-grade cervical intraepithelial neoplasia with TG4001 targeted immunotherapy Am J Obstet Gynecol 204 2011 169.e1 169.e8
60. M.J. Welters, G.G. Kenter, and S.J. Piersma Induction of tumor-specific CD4 + and CD8 + T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine Clin Cancer Res 14 2008 178 187
61. G.G. Kenter, M.J. Welters, and A.R. Valentijn Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia N Engl J Med 361 2009 1838 1847
62. M.H. Einstein, A.S. Kadish, and R.D. Burk Heat shock fusion protein-based immunotherapy for treatment of cervical intraepithelial neoplasia III Gynecol Oncol 106 2007 453 460
63. I.H. Frazer, M. Quinn, and J.L. Nicklin Phase 1 study of HPV16-specific immunotherapy with E6E7 fusion protein and ISCOMATRIX adjuvant in women with cervical intraepithelial neoplasia Vaccine 23 2004 172 181
64. L.D. Roman, S. Wilczynski, and L.I. Muderspach A phase II study of Hsp-7 (SGN-00101) in women with high-grade cervical intraepithelial neoplasia Gynecol Oncol 106 2007 558 566
65. J.M. Palefsky, J.M. Berry, and N. Jay A trial of SGN-00101 (HspE7) to treat high-grade anal intraepithelial neoplasia in HIV-positive individuals AIDS 20 2006 1151 1155
66. S. Daayana, E. Elkord, and U. Winters Phase II trial of imiquimod and HPV therapeutic vaccination in patients with vulval intraepithelial neoplasia Br J Cancer 102 2010 1129 1136
67. C.L. Trimble, S. Peng, and F. Kos A phase I trial of a human papillomavirus DNA vaccine for HPV16 + cervical intraepithelial neoplasia 2/3 Clin Cancer Res 15 1 2009 361 367
68. F. Garcia, K.U. Petry, and L. Muderspach ZYC101a for treatment of high-grade cervical intraepithelial neoplasia: a randomized controlled trial Obstet Gynecol 103 2004 317 326
69. A. Ferrara, M. Nonn, and P. Sehr Dendritic cell-based tumor vaccine for cervical cancer II: results of a clinical pilot study in 15 individual patients J Cancer Res Clin Oncol 129 2003 521 530
70. A.D. Santin, S. Bellone, and M. Palmieri Human papillomavirus type 16 and 18 E7-pulsed dendritic cell vaccination of stage IB or IIA cervical cancer patients: a phase I escalating-dose trial J Virol 82 2008 1968 1979